A genetic polymorphism of MAO-B modifies the association of cigarette smoking and Parkinson's disease

被引：77
|
作者：
Checkoway, H
Franklin, GM
Costa-Mallen, P
Smith-Weller, T
Dilley, J
Swanson, PD
Costa, LG
机构：
[1] Univ Washington, Dept Environm Hlth, Seattle, WA 98195 USA
[2] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA
[3] Univ Washington, Dept Neurol, Seattle, WA 98195 USA
来源：
NEUROLOGY | 1998年 / 50卷 / 05期
关键词：
D O I：
10.1212/WNL.50.5.1458
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
In a population-based case-control study, we found a reversal of the association of cigarette smoking with Parkinson's disease (PD) in relation to the monoamine oxidase B intron 13 genetic polymorphism. A reduced PD risk related to pack-years of smoking was detected for persons with the G allele, whereas an opposite effect was found among persons with the A allele. These results indicate an unexplained interaction between cigarette smoking and this genetic polymorphism.
引用
收藏
页码：1458 / 1461
页数：4
相关论文
共 50 条
  • [21] Mitochondrial complex I polymorphism and cigarette smoking in Parkinson's disease
    Tan, EK
    Chai, A
    Zhao, Y
    Lum, SY
    Fook-Chong, SMC
    Teoh, ML
    Yih, Y
    Pavanni, R
    Wong, MC
    NEUROLOGY, 2002, 59 (08) : 1288 - 1289
  • [22] NOVEL MAO-B INHIBITORS: POTENTIAL THERAPEUTIC USE OF THE SELECTIVE MAO-B INHIBITOR PF9601N IN PARKINSON'S DISEASE
    Unzeta, Mercedes
    Sanz, Elisenda
    MONOAMINE OXIDASES AND THEIR INHIBITORS, 2011, 100 : 217 - 236
  • [23] Neuroprotection of MAO-B inhibitor and dopamine agonist in Parkinson disease
    Kong, Ping
    Zhang, Benshu
    Lei, Ping
    Kong, Xiaodong
    Zhang, Shishuang
    Li, Dai
    Zhang, Yun
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2015, 8 (01): : 431 - 439
  • [24] Clinical benefit of MAO-B and COMT inhibition in Parkinson’s disease: practical considerations
    Martin Regensburger
    Chi Wang Ip
    Zacharias Kohl
    Christoph Schrader
    Peter P. Urban
    Jan Kassubek
    Wolfgang H. Jost
    Journal of Neural Transmission, 2023, 130 : 847 - 861
  • [25] Clinical benefit of MAO-B and COMT inhibition in Parkinson's disease: practical considerations
    Regensburger, Martin
    Ip, Chi Wang
    Kohl, Zacharias
    Schrader, Christoph
    Urban, Peter P.
    Kassubek, Jan
    Jost, Wolfgang H.
    JOURNAL OF NEURAL TRANSMISSION, 2023, 130 (06) : 847 - 861
  • [26] Gamma-decanolactone as selective MAO-B inhibitor in Parkinson's disease treatment
    Pfluger, Pricila
    Pereira, Patricia
    Vina, Dolores
    Fontenla, Jose A.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2019, 125 : 42 - 42
  • [27] MAO-B G polymorphism influences time to onset of parkin-sonian symptoms in male Parkinson's disease patients
    Schuh, A. S.
    Rieder, C. R. M.
    Altmann, V.
    Francisconi, C. M.
    Monte, T. L.
    Hutz, M. H.
    MOVEMENT DISORDERS, 2010, 25 (07) : S478 - S478
  • [28] Monoamine oxidase B polymorphism, cigarette smoking and risk of Parkinson's disease: A study in an Asian population
    Tan, EK
    Chai, A
    Lum, SY
    Shen, H
    Tan, C
    Teoh, ML
    Yih, Y
    Wong, MC
    Zha, Y
    AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS, 2003, 120B (01) : 58 - 62
  • [29] Monoamine oxidase-B (MAO-B) inhibitors: Implications for disease-modification in Parkinson's disease
    Teo K.C.
    Ho S.-L.
    Translational Neurodegeneration, 2 (1)
  • [30] Association between cigarette smoking and Parkinson's disease: a neuroimaging study
    Wang, Chao
    Zhou, Cheng
    Guo, Tao
    Huang, Peiyu
    Xu, Xiaojun
    Zhang, Minming
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2022, 15
12345